
|Articles|November 1, 2003
Prophylactic mitomycin-C limits haze, regression in PRK
Montreal-PRK using adjunctive intraoperative mitomycin-C (Mutamycin, Bristol-Myers Squibb) is a safe and effective tech- nique for treating eyes with high myopia, thin corneas, and large pupils, according to Pierre E. Demers, MD.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Ocular Therapeutix accelerates NDA submission plans for AXPAXLI for wet AMD
2
ONL Therapeutics reports positive phase 1b data for xelafaslatide in geographic atrophy
3
FDA grants IDE approval to EyeYon Medical for its US clinical study of EndoArt
4
Study maps thermal dynamics of glaucoma laser treatments
5















































.png)


